ERG and prostate carcinoma: A recently identified downstream target of ERG is CBP/p300-interacting transactivator 2 (CITED2), a molecular chaperone that promotes the translocation of p300 and protein arginine N-methyltransferase 5 (PRMT5) and the formation of a multimeric complex with nucleolin which stimulates cell migration, ultimately leading to prostate cancer metastasis [118].